← Evidence map

ArticleAIDS and behavior2026

Patient-Reported Outcomes Among Virally Suppressed People Living with HIV Switching to Dolutegravir/Lamivudine vs. Continuing Bictegravir/Emtricitabine/Tenofovir Alafenamide from the Randomized DYAD Study.

Charlotte-Paige Rolle et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Patient-Reported Outcomes Among Virally Suppressed People Living with HIV Switching to Dolutegravir/Lamivudine vs. Continuing Bictegravir/Emtricitabine/Tenofovir Alafenamide from the Randomized DYAD Study. | Socratic